Trial Site News
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
  • Register
  • Log In
  • News
  • Video
  • Podcast
  • More
Trial Site News
  • News For You
  • Op-Eds
  • Video
  • Podcasts
  • Investor Watch
  • Write for us
  • News for You
  • Op-Eds
  • Video
  • Podcasts
  • Covid-19
  • Investor Watch

Topic: Immunology

Salk Institute Full Throttle Securing $10.7m Just in January for Research Including Microbiome & Inflammation Plus Aging & Dementia

Despite pandemic, economic rollercoaster, nasty politics and a host of other challenges faced, things are looking brighter in delightful La […]

Salk Institute Full Throttle Securing $10.7m Just in January for Research Including Microbiome & Inflammation Plus Aging & Dementia
1 month ago
Share

Dr. Shao-Cong Sun & Team Identify Protein Important for T Cell Metabolism & Anti-Tumor Immune Response

University of Texas MD Anderson Cancer Center researchers along with a colleague from Genentech (Roche) and Seoul National University in […]

Dr. Shao-Cong Sun & Team Identify Protein Important for T Cell Metabolism & Anti-Tumor Immune Response
2 months ago
Share

NeuroGenesis and Hadassah Medical Center Report Significant Results in Patients with Progressive Multiple Sclerosis Treated with NG-01 Autologous Cells Therapy

NeuroGenesis and Hadassah Medical Center announced highly positive results from a placebo-controlled Phase 2 clinical trial assessing the impact of […]

NeuroGenesis and Hadassah Medical Center Report Significant Results in Patients with Progressive Multiple Sclerosis Treated with NG-01 Autologous Cells Therapy
3 months ago
Share

TG Therapeutics Reports Ublituximab Outperforms Sanofi Genzyme’s Aubagio in Relapsing Forms of MS in Two Phase 3 Trials

TG Therapeutics announced positive topline results from two global, active-controlled, Phase 3 studies, called ULTIMATE I & II, evaluating ublituximab […]

TG Therapeutics Reports Ublituximab Outperforms Sanofi Genzyme’s Aubagio in Relapsing Forms of MS in Two Phase 3 Trials
3 months ago
Share

Gilead Reports Data from Phase 2/3 CAPELLA Trial Evaluating Long-Acting HIV-1 Capsid Inhibitor in Heavily Pre-Treated Patients with MDR HIV-1 Infection

Gilead announced topline results from the Phase 2/3 CAPELLA trial evaluating lenacapavir versus placebo in heavily treatment-experienced patients with multidrug […]

Gilead Reports Data from Phase 23 CAPELLA Trial Evaluating Long-Acting HIV-1 Capsid Inhibitor in Heavily Pre-Treated Patients with MDR HIV-1 Infection
4 months ago
Share

Cleveland Research Centers Receive $2.6m & Participate in NCI’s ‘SeroNet’ Study of Human Immune Responses to COVID-19

The National Cancer Institute (NCI) injected $2.6 million into research involving two studies led by Case Western Reserve University and […]

Cleveland Research Centers Receive $2.6m & Participate in NCI’s ‘SeroNet’ Study of Human Immune Responses to COVID-19
4 months ago
Share

University of Arizona Health Sciences Presents Early Data from Personalized Cancer Vaccine Clinical Trial, Patient Enrollment Now Expanding

Preliminary data from a phase 1 study, designed to evaluate the safety and efficacy of a personalized cancer vaccine in […]

University of Arizona Health Sciences Presents Early Data from Personalized Cancer Vaccine Clinical Trial, Patient Enrollment Now Expanding
4 months ago
Share

Arena Pharma’s Etrasimod Effective in Treating Atopic Dermatitis in Phase 2b Trial

Arena Pharmaceuticals announced topline results from the Phase 2b ADVISE clinical trial evaluating etrasimod for the treatment of moderate-to-severe atopic […]

Arena Pharma’s Etrasimod Effective in Treating Atopic Dermatitis in Phase 2b Trial
4 months ago
Share

Bristol Myers Squibb’s Deucravacitinib Superior to Amgen’s Otezla (apremilast) and Placebo in Pivotal Phase 3 Psoriasis Study

Bristol-Myers Squibb reported positive results from POETYK PSO-1, the first pivotal Phase 3 trial evaluating deucravacitinib (BMS-986165) versus Otezla (apremilast) […]

Bristol Myers Squibb’s Deucravacitinib Superior to Amgen’s Otezla (apremilast) and Placebo in Pivotal Phase 3 Psoriasis Study
4 months ago
Share

Biogen Reports Data for Systemic Lupus Erythematosus Portion of Phase 2 LILAC Study Showing Efficacy of BIIB059 in Reducing Joint Disease Activity

Biogen announced positive data from the 24-week systemic lupus erythematosus (SLE) portion of the Phase 2 LILAC study (part A) […]

Biogen Reports Data for Systemic Lupus Erythematosus Portion of Phase 2 LILAC Study Showing Efficacy of BIIB059 in Reducing Joint Disease Activity
4 months ago
Share

Posts navigation

Older posts

Latest Podcasts

Alan Cannell talks COVID-19: Nobody Likes Cheap Solutions | Podcast S2 E41

Dr. Pierre Kory Talks Covid-19, Ivermectin and the FLCCC | Podcast E43

An Interview With Patricia Carter: Patient Engagement and Retention in Clinical Trials

Dr. Negin Hajizadeh: Researchers Finding A Very Effective Treatment For Covid-19 In New Study

Dr. Jean-Jacques Rajter and Dr. Juliana Cepelowicz Rajter Discuss Ivermectin In Broward County | Podcast S2 E 27

159 W Broadway, Suite 200
Salt Lake City, UT 84101

[email protected]

Connect With Us

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

© 2021 TRIALSITE NEWS. ALL RIGHTS RESERVED.